{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:44:54Z","timestamp":1792007094836,"version":"4.4.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1038\/ncpendmet0394","type":"journal-article","created":{"date-parts":[[2007,1,22]],"date-time":"2007-01-22T12:44:32Z","timestamp":1169469872000},"page":"134-144","source":"Crossref","is-referenced-by-count":67,"title":["Drug Insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease"],"prefix":"10.1038","volume":"3","author":[{"given":"Alex J","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Slatopolsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpendmet0394_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1152\/physrev.1991.71.2.371","volume":"71","author":"EM Brown","year":"1991","unstructured":"Brown EM (1991) Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. Physiol Rev 71: 371\u2013411","journal-title":"Physiol Rev"},{"key":"BFncpendmet0394_CR2","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/0006-291X(75)90391-5","volume":"62","author":"HL Henry","year":"1975","unstructured":"Henry HL and Norman AW (1975) Studies on the mechanism of action of calciferol. VII. Localization of 1,25-dihydroxy-vitamin D3 in chick parathyroid glands. Biochem Biophys Res Commun 62: 781\u2013788","journal-title":"Biochem Biophys Res Commun"},{"key":"BFncpendmet0394_CR3","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1172\/JCI112714","volume":"78","author":"J Silver","year":"1986","unstructured":"Silver J et al. (1986) Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 78: 1296\u20131301","journal-title":"J Clin Invest"},{"key":"BFncpendmet0394_CR4","first-page":"256","volume":"100","author":"J Russell","year":"1987","unstructured":"Russell J and Sherwood LM (1987) The effects of 1,25-dihydroxyvitamin D3 and high calcium on transcription of the pre-proparathyroid hormone gene are direct. Transact Assoc Am Physicians 100: 256\u2013262","journal-title":"Transact Assoc Am Physicians"},{"key":"BFncpendmet0394_CR5","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1210\/endo-125-2-935","volume":"125","author":"R Kremer","year":"1989","unstructured":"Kremer R et al. (1989) Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology 125: 935\u2013941","journal-title":"Endocrinology"},{"key":"BFncpendmet0394_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF02555137","volume":"43","author":"P Nygren","year":"1988","unstructured":"Nygren P et al. (1988) 1,25(OH)2D3 inhibits hormone secretion and proliferation but not functional dedifferentiation of cultured bovine parathyroid cells. Calcif Tissue Int 43: 213\u2013218","journal-title":"Calcif Tissue Int"},{"issue":"Suppl","key":"BFncpendmet0394_CR7","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","volume":"73","author":"E Slatopolsky","year":"1999","unstructured":"Slatopolsky E et al. (1999) Pathogenesis of secondary hyperparathyroidism. Kidney Int 73 (Suppl): S14\u2013S19","journal-title":"Kidney Int"},{"key":"BFncpendmet0394_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1053\/j.ajkd.2003.12.003","volume":"43","author":"KJ Martin","year":"2004","unstructured":"Martin KJ et al. (2004) Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 43: 558\u2013565","journal-title":"Am J Kidney Dis"},{"key":"BFncpendmet0394_CR9","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1248\/cpb.34.4410","volume":"34","author":"E Murayama","year":"1986","unstructured":"Murayama E et al. (1986) Synthetic studies of vitamin D3 analogues. VIII. Synthesis of 22-oxavitamin D3 analogues. Chem Pharm Bull (Tokyo) 34: 4410\u20134413","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"BFncpendmet0394_CR10","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1172\/JCI114229","volume":"84","author":"AJ Brown","year":"1989","unstructured":"Brown AJ et al. (1989) The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84: 728\u2013732","journal-title":"J Clin Invest"},{"issue":"Suppl 29","key":"BFncpendmet0394_CR11","first-page":"S22","volume":"29","author":"AJ Brown","year":"1990","unstructured":"Brown AJ et al. (1990) New active analogues of vitamin D with low calcemic activity. Kidney Int 29 (Suppl 29): S22\u2013S27","journal-title":"Kidney Int"},{"key":"BFncpendmet0394_CR12","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1210\/endo.133.6.8243296","volume":"133","author":"T Naveh-Many","year":"1993","unstructured":"Naveh-Many T and Silver J (1993) Effects of calcitriol, 22-oxacalcitriol, and calcipotriol on serum calcium and parathyroid hormone gene expression. Endocrinology 133: 2724\u20132728","journal-title":"Endocrinology"},{"key":"BFncpendmet0394_CR13","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1046\/j.1523-1755.1999.00772.x","volume":"56","author":"M Hirata","year":"1999","unstructured":"Hirata M et al. (1999) 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis. Kidney Int 56: 2040\u20132047","journal-title":"Kidney Int"},{"issue":"Suppl 10","key":"BFncpendmet0394_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/ndt\/17.suppl_10.41","volume":"17","author":"M Hirata","year":"2002","unstructured":"Hirata M et al. (2002) A comparison between 1,25-dihydroxy-22-oxavitamin D3 and 1,25-dihydroxyvitamin D3 regarding suppression of parathyroid hormone and calcemic action. Nephrol Dial Transplant 17 (Suppl 10): 41\u201345","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpendmet0394_CR15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1046\/j.1523-1755.1999.055003821.x","volume":"55","author":"MC Monier-Faugere","year":"1999","unstructured":"Monier-Faugere MC et al. (1999) 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int 55: 821\u2013832","journal-title":"Kidney Int"},{"key":"BFncpendmet0394_CR16","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/ndt\/gfg296","volume":"18","author":"M Hirata","year":"2003","unstructured":"Hirata M et al. (2003) In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3 . Nephrol Dial Transplant 18: 1770\u20131776","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpendmet0394_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3177\/jnsv.35.529","volume":"35","author":"T Okano","year":"1989","unstructured":"Okano T et al. (1989) Protein-binding properties of 22-oxa-1\u03b1,25-dihydroxyvitamin D3, a synthetic analogue of 1\u03b1,25-dihydroxyvitamin D3 . J Nutr Sci Vitaminol (Tokyo) 35: 529\u2013533","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"key":"BFncpendmet0394_CR18","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1210\/endo-128-4-1687","volume":"128","author":"AS Dusso","year":"1991","unstructured":"Dusso AS et al. (1991) On the mechanisms for the selective action of vitamin D analogs. Endocrinology 128: 1687\u20131692","journal-title":"Endocrinology"},{"key":"BFncpendmet0394_CR19","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1210\/endo.133.3.8396012","volume":"133","author":"AJ Brown","year":"1993","unstructured":"Brown AJ et al. (1993) The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 133: 1158\u20131164","journal-title":"Endocrinology"},{"key":"BFncpendmet0394_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/oxfordjournals.jbchem.a124346","volume":"115","author":"T Kobayashi","year":"1994","unstructured":"Kobayashi T et al. (1994) The binding properties, with blood proteins, and tissue distribution of 22-oxa-1\u03b1,25-dihydroxyvitamin D3, a noncalcemic analogue of 1\u03b1,25-dihydroxyvitamin D3, in rats. J Biochem 115: 373\u2013380","journal-title":"J Biochem"},{"issue":"Suppl 10","key":"BFncpendmet0394_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/ndt\/17.suppl_10.53","volume":"17","author":"N Koike","year":"2002","unstructured":"Koike N et al. (2002) In vivo time-course of receptor binding in the parathyroid gland of the vitamin D analogue [3H]1,25-dihydroxy-22-oxavitamin D3 compared to [3H]1,25-dihydroxyvitamin D3, determined by micro-autoradiography. Nephrol Dial Transplant 17 (Suppl 10): 53\u201357","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpendmet0394_CR22","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1128\/MCB.19.2.1049","volume":"19","author":"K Takeyama","year":"1999","unstructured":"Takeyama K et al. (1999) Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol Cell Biol 19: 1049\u20131055","journal-title":"Mol Cell Biol"},{"issue":"Suppl 3","key":"BFncpendmet0394_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/ndt\/11.supp3.121","volume":"11","author":"K Kurokawa","year":"1996","unstructured":"Kurokawa K et al. (1996) Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study. Nephrol Dial Transplant 11 (Suppl 3): 121\u2013124","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 10","key":"BFncpendmet0394_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/ndt\/17.suppl_10.28","volume":"17","author":"T Akizawa","year":"2002","unstructured":"Akizawa T et al. (2002) Long-term effect of 1,25-dihydroxy-22-oxavitamin D3 on secondary hyperparathyroidism in haemodialysis patients. One-year administration study. Nephrol Dial Transplant 17 (Suppl 10): 28\u201336","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"BFncpendmet0394_CR25","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1053\/ajkd.2003.50097","volume":"41","author":"M Yasuda","year":"2003","unstructured":"Yasuda M et al. (2003) Multicenter clinical trial of 22-oxa-1,25-dihydroxyvitamin D3 for chronic dialysis patients. Am J Kidney Dis 41 (Suppl 1): S108\u2013S111","journal-title":"Am J Kidney Dis"},{"key":"BFncpendmet0394_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1774-9987.2004.00191.x","volume":"8","author":"T Akizawa","year":"2004","unstructured":"Akizawa T et al. (2004) Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism. Ther Apher Dial 8: 480\u2013491","journal-title":"Ther Apher Dial"},{"key":"BFncpendmet0394_CR27","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1093\/ndt\/gfh329","volume":"19","author":"M Hayashi","year":"2004","unstructured":"Hayashi M et al. (2004) Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial. Nephrol Dial Transplant 19: 2067\u20132073","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpendmet0394_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s10157-005-0363-x","volume":"9","author":"S Tamura","year":"2005","unstructured":"Tamura S et al. (2005) Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients. Clin Exp Nephrol 9: 238\u2013243","journal-title":"Clin Exp Nephrol"},{"key":"BFncpendmet0394_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s10157-005-0342-2","volume":"9","author":"Y Oyama","year":"2005","unstructured":"Oyama Y et al. (2005) Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 9: 142\u2013147","journal-title":"Clin Exp Nephrol"},{"key":"BFncpendmet0394_CR30","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/0272-6386(95)90455-7","volume":"26","author":"E Slatopolsky","year":"1995","unstructured":"Slatopolsky E et al. (1995) A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 26: 852\u2013860","journal-title":"Am J Kidney Dis"},{"key":"BFncpendmet0394_CR31","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1046\/j.1523-1755.2003.00029.x","volume":"63","author":"E Slatopolsky","year":"2003","unstructured":"Slatopolsky E et al. (2003) Efficacy of 19-nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Kidney Int 63: 2020\u20132027","journal-title":"Kidney Int"},{"key":"BFncpendmet0394_CR32","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/ki.1989.89","volume":"35","author":"A Szabo","year":"1989","unstructured":"Szabo A et al. (1989) 1,25(OH)2vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 35: 1049\u20131056","journal-title":"Kidney Int"},{"key":"BFncpendmet0394_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0272-6386(97)90571-0","volume":"30","author":"F Takahashi","year":"1997","unstructured":"Takahashi F et al. (1997) A new analog of 1,25-(OH)2D3, 19-nor-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 30: 105\u2013112","journal-title":"Am J Kidney Dis"},{"key":"BFncpendmet0394_CR34","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1046\/j.1523-1755.2001.00042.x","volume":"60","author":"M Cozzolino","year":"2001","unstructured":"Cozzolino M et al. (2001) p21WAF1 and TGF-\u03b1 mediate the parathyroid growth arrest by vitamin D and high calcium. Kidney Int 60: 2109\u20132117","journal-title":"Kidney Int"},{"key":"BFncpendmet0394_CR35","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","volume":"9","author":"KJ Martin","year":"1998","unstructured":"Martin KJ et al. (1998) 19-Nor-1\u03b1,25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9: 1427\u20131432","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 2","key":"BFncpendmet0394_CR36","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1053\/ajkd.1998.v32.pm9808145","volume":"32","author":"KJ Martin","year":"1998","unstructured":"Martin KJ et al. (1998) Therapy of secondary hyperparathyroidism with 19-nor-1\u03b1,25-dihydroxyvitamin D2 . Am J Kidney Dis 32 (Suppl 2): S61\u2013S66","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 5","key":"BFncpendmet0394_CR37","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1053\/ajkd.2001.28112","volume":"38","author":"KJ Martin","year":"2001","unstructured":"Martin KJ et al. (2001) Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized trial. Am J Kidney Dis 38 (Suppl 5): S57\u2013S63","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 5","key":"BFncpendmet0394_CR38","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","volume":"38","author":"F Llach","year":"2001","unstructured":"Llach F and Yudd M (2001) Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 38 (Suppl 5): S45\u2013S50","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 5","key":"BFncpendmet0394_CR39","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1053\/ajkd.2001.28110","volume":"38","author":"SM Sprague","year":"2001","unstructured":"Sprague SM et al. (2001) Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 38 (Suppl 5): S51\u2013S56","journal-title":"Am J Kidney Dis"},{"key":"BFncpendmet0394_CR40","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"SM Sprague","year":"2003","unstructured":"Sprague SM et al. (2003) Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63: 1483\u20131490","journal-title":"Kidney Int"},{"key":"BFncpendmet0394_CR41","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1056\/NEJMoa022536","volume":"349","author":"M Teng","year":"2003","unstructured":"Teng M et al. (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446\u2013456","journal-title":"N Engl J Med"},{"key":"BFncpendmet0394_CR42","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1093\/ndt\/gfh123","volume":"19","author":"DG Dobrez","year":"2004","unstructured":"Dobrez DG et al. (2004) Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 19: 1174\u20131181","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpendmet0394_CR43","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1681\/ASN.2004070573","volume":"16","author":"M Teng","year":"2005","unstructured":"Teng M et al. (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16: 1115\u20131125","journal-title":"J Am Soc Nephrol"},{"key":"BFncpendmet0394_CR44","doi-asserted-by":"publisher","first-page":"279A","DOI":"10.1681\/ASN.2004121119","volume":"16","author":"F Tentori","year":"2005","unstructured":"Tentori F et al. (2005) Survival among hemodialysis patients receiving intravenous doxercalciferol and paricalcitol versus calcitriol [abstract #TH-PO737]. J Am Soc Nephrol 16: 279A","journal-title":"J Am Soc Nephrol"},{"key":"BFncpendmet0394_CR45","doi-asserted-by":"publisher","first-page":"279A","DOI":"10.1681\/ASN.2004121119","volume":"16","author":"F Tentori","year":"2005","unstructured":"Tentori F et al. (2005) Decreased odds of hospitalization among hemodialysis patients receiving doxercalciferol and paricalcitol versus calcitriol [abstract #TH-PO738]. J Am Soc Nephrol 16: 279A","journal-title":"J Am Soc Nephrol"},{"key":"BFncpendmet0394_CR46","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3181\/00379727-178-42028","volume":"178","author":"G Sjoden","year":"1985","unstructured":"Sjoden G et al. (1985) 1\u03b1-Hydroxyvitamin D2 is less toxic than 1\u03b1-hydroxyvitamin D3 in the rat. Proc Soc Exp Biol Med 178: 432\u2013436","journal-title":"Proc Soc Exp Biol Med"},{"key":"BFncpendmet0394_CR47","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/ki.1997.39","volume":"51","author":"AU Tan Jr","year":"1997","unstructured":"Tan AU Jr et al. (1997) Effective suppression of parathyroid hormone by 1\u03b1-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 51: 317\u2013323","journal-title":"Kidney Int"},{"key":"BFncpendmet0394_CR48","first-page":"583","volume":"26","author":"JM Frazao","year":"1997","unstructured":"Frazao JM et al. (1997) Efficacy and safety of intermittent oral 1\u03b1-(OH)-vitamin D2 in suppressing secondary hyperparathyroidism in hemodialysis patients. Nephrol Dial Transplant 26: 583\u2013595","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpendmet0394_CR49","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/ndt\/13.suppl_3.68","volume":"3","author":"JM Frazao","year":"1998","unstructured":"Frazao JM et al. (1998) Intermittent oral 1\u03b1hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. Nephrol Dial Transplant 3: 68\u201372","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpendmet0394_CR50","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1053\/ajkd.2001.22077","volume":"37","author":"HM Maung","year":"2001","unstructured":"Maung HM et al. (2001) Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1\u03b1-hydroxyvitamin D2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 37: 532\u2013543","journal-title":"Am J Kidney Dis"},{"key":"BFncpendmet0394_CR51","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/j.1523-1755.2002.kid573.x","volume":"62","author":"E Slatopolsky","year":"2002","unstructured":"Slatopolsky E et al. (2002) Differential effects of 19-nor-1,25-(OH)2D2 and 1\u03b1-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic rats. Kidney Int 62: 1277\u20131284","journal-title":"Kidney Int"},{"key":"BFncpendmet0394_CR52","first-page":"495A","volume":"16","author":"GA Reinhart","year":"2005","unstructured":"Reinhart GA et al. (2005) Differential effects of paricalcitol and doxercalciferol on serum PTH and ionized calcium in uremic rats with established secondary hyperparathyroidism [abstract]. J Am Soc Nephrol 16: 495A","journal-title":"J Am Soc Nephrol"},{"key":"BFncpendmet0394_CR53","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1159\/000089707","volume":"25","author":"AL Zisman","year":"2005","unstructured":"Zisman AL et al. (2005) Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol 25: 591\u2013595","journal-title":"Am J Nephrol"},{"key":"BFncpendmet0394_CR54","doi-asserted-by":"publisher","first-page":"335","DOI":"10.5414\/CNP65335","volume":"65","author":"HE Joist","year":"2006","unstructured":"Joist HE et al. (2006) Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphate. Clin Nephrol 65: 335\u2013341","journal-title":"Clin Nephrol"},{"key":"BFncpendmet0394_CR55","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0960-0760(99)00112-0","volume":"70","author":"Y Imanishi","year":"1999","unstructured":"Imanishi Y et al. (1999) Increased biological potency of hexafluorinated analogs of 1,25-dihydroxyvitamin D3 on bovine parathyroid cells. J Steroid Biochem Mol Biol 70: 243\u2013248","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BFncpendmet0394_CR56","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1124\/dmd.31.8.973","volume":"31","author":"S Komuro","year":"2003","unstructured":"Komuro S et al. (2003) Disposition and metabolism of F6-1\u03b1,25(OH)2 vitamin D3 and 1\u03b1,25(OH)2 vitamin D3 in the parathyroid glands of rats dosed with tritium-labeled compounds. Drug Metab Dispos 31: 973\u2013978","journal-title":"Drug Metab Dispos"},{"key":"BFncpendmet0394_CR57","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000420143","volume":"90","author":"Y Nishizawa","year":"1991","unstructured":"Nishizawa Y et al. (1991) Clinical trial of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 in uremic patients on hemodialysis: preliminary report. Contrib Nephrol 90: 196\u2013203","journal-title":"Contrib Nephrol"},{"key":"BFncpendmet0394_CR58","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1053\/ajkd.1998.v32.pm9708607","volume":"32","author":"T Akiba","year":"1998","unstructured":"Akiba T et al. (1998) Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 32: 238\u2013246","journal-title":"Am J Kidney Dis"},{"key":"BFncpendmet0394_CR59","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/ndt\/11.supp3.22","volume":"11","author":"I Martinez","year":"1996","unstructured":"Martinez I et al. (1996) A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 11: 22\u201328","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpendmet0394_CR60","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1053\/snep.2002.35965","volume":"22","author":"LT Ho","year":"2002","unstructured":"Ho LT and Sprague SM (2002) Renal osteodystrophy in chronic renal failure. Semin Nephrol 22: 488\u2013493","journal-title":"Semin Nephrol"},{"issue":"Suppl 3","key":"BFncpendmet0394_CR61","first-page":"S1","volume":"42","author":"G Eknoyan","year":"2004","unstructured":"Eknoyan G et al. (2004) K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3): S1\u2013S201","journal-title":"Am J Kidney Dis"},{"key":"BFncpendmet0394_CR62","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/archinte.1980.00330190042017","volume":"140","author":"MD Healy","year":"1980","unstructured":"Healy MD et al. (1980) Effects of long-term therapy with calcitriol in patients with moderate renal failure. Arch Intern Med 140: 1030\u20131033","journal-title":"Arch Intern Med"},{"key":"BFncpendmet0394_CR63","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/ki.1989.36","volume":"35","author":"LR Baker","year":"1989","unstructured":"Baker LR et al. (1989) 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 35: 661\u2013669","journal-title":"Kidney Int"},{"key":"BFncpendmet0394_CR64","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1053\/j.ajkd.2004.01.012","volume":"43","author":"JW Coburn","year":"2004","unstructured":"Coburn JW et al. (2004) Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 43: 877\u2013890","journal-title":"Am J Kidney Dis"},{"key":"BFncpendmet0394_CR65","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","volume":"47","author":"D Coyne","year":"2006","unstructured":"Coyne D et al. (2006) Paricalcitol capsule for treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47: 263\u2013276","journal-title":"Am J Kidney Dis"},{"key":"BFncpendmet0394_CR66","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1093\/ndt\/15.12.1943","volume":"15","author":"SLS Fan","year":"2000","unstructured":"Fan SLS et al. (2000) Potent suppression of the parathyroid glands by hydroxylated metabolites of dihydrotachysterol2 . Nephrol Dial Transplant 15: 1943\u20131949","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpendmet0394_CR67","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1093\/ndt\/11.9.1781","volume":"11","author":"M Hruby","year":"1996","unstructured":"Hruby M et al. (1996) Effects of new vitamin D analogues on parathyroid function in chronically uraemic rats with secondary hyperparathyroidism. Nephrol Dial Transplant 11: 1781\u20131786","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpendmet0394_CR68","first-page":"7","volume":"61","author":"K Lippuner","year":"2004","unstructured":"Lippuner K et al. (2004) 1,25-(OH)2-16ene-23yne-D3 reduces secondary hyperparathyroidism in uremic rats with little calcemic effect. Horm Res 61: 7\u201316","journal-title":"Horm Res"},{"key":"BFncpendmet0394_CR69","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/jcb.20553","volume":"96","author":"AJ Brown","year":"2005","unstructured":"Brown AJ et al. (2005) Isolation and identification of 1\u03b1-hydroxy-3-epi-vitamin D3, a potent suppressor of parathyroid hormone secretion. J Cell Biochem 96: 569\u2013578","journal-title":"J Cell Biochem"},{"key":"BFncpendmet0394_CR70","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.1073\/pnas.0401656101","volume":"101","author":"LA Plum","year":"2004","unstructured":"Plum LA et al. (2004) Biologically active noncalcemic analogs of 1\u03b1,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl. Proc Natl Acad Sci USA 101: 6900\u20136904","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpendmet0394_CR71","doi-asserted-by":"publisher","first-page":"48A","DOI":"10.1097\/01.ASN.0000081668.41546.2B","volume":"14","author":"E Slatopolsky","year":"2003","unstructured":"Slatopolsky E et al. (2003) A new vitamin D analog without calcemic and phosphatemic effects [abstract #SU-FC220]. J Am Soc Nephrol 14: 48A","journal-title":"J Am Soc Nephrol"},{"key":"BFncpendmet0394_CR72","first-page":"2967","volume":"87","author":"U Segersten","year":"2002","unstructured":"Segersten U et al. (2002) 25-hydroxyvitamin D3-1\u03b1-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab 87: 2967\u20132972","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0394_CR73","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/sj.ki.5000394","volume":"70","author":"CS Ritter","year":"2006","unstructured":"Ritter CS et al. (2006) 25-Hydroxyvitamin D3 suppresses PTH synthesis and secretion by cultured bovine parathyroid cells: potential role for intracrine 1,25-dihydroxyvitamin D3 . Kidney Int 70: 654\u2013659","journal-title":"Kidney Int"},{"key":"BFncpendmet0394_CR74","doi-asserted-by":"publisher","first-page":"5826","DOI":"10.1210\/jc.2002-021356","volume":"87","author":"P Correa","year":"2002","unstructured":"Correa P et al. (2002) Increased 25-hydroxyvitamin D3 1\u03b1-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase in parathyroid tumors\u2014new prospects for treatment of hyperparathyroidism with vitamin D. J Clin Endocrinol Metab 87: 5826\u20135829","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0394_CR75","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1523-1755.1999.00240.x","volume":"55","author":"EA Slatopolsky","year":"1999","unstructured":"Slatopolsky EA et al. (1999) RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 55: 299\u2013307","journal-title":"Kidney Int"},{"key":"BFncpendmet0394_CR76","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/j.1368-5031.2005.00592.x","volume":"59","author":"F Albaaj","year":"2005","unstructured":"Albaaj F and Hutchison AJ (2005) Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients. Int J Clin Pract 59: 1091\u20131096","journal-title":"Int J Clin Pract"},{"key":"BFncpendmet0394_CR77","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/01.mnh.0000172722.52499.71","volume":"14","author":"WG Goodman","year":"2005","unstructured":"Goodman WG (2005) Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease? Curr Opin Nephrol Hypertens 14: 355\u2013360","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"BFncpendmet0394_CR78","first-page":"2255","volume-title":"The Kidney","author":"KJ Martin","year":"2004","unstructured":"Martin KJ et al. (2004) Renal osteodystrophy. In The Kidney, edn 7, 2255\u20132304 (Ed. Brenner BM) Philadelphia: WB Saunders"}],"container-title":["Nature Clinical Practice Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0394","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T19:51:41Z","timestamp":1684439501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpendmet0394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["BFncpendmet0394"],"URL":"https:\/\/doi.org\/10.1038\/ncpendmet0394","relation":{},"ISSN":["1745-8366","1745-8374"],"issn-type":[{"value":"1745-8366","type":"print"},{"value":"1745-8374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}